Table 3.
Overview of studies that identified c-miRs as biomarkers to distinguish OP patients wF from CTRs wnOF.
| Study Design | OP Diagnosis | c-miRs Source | Platforms for c-miR Quantification | Validate c-miR Biomarkers |
Normalization Strategy | AUC Value | c-miR Correlations |
Ref | |
|---|---|---|---|---|---|---|---|---|---|
| Prescreening | Validation | ||||||||
| OP F (40), CTR wnOF (40) | DXA | Serum | qPCR array | qPCR | miR-21-5p, miR-23a-3p, miR-24-3p, miR-100-5p, miR-122-5p, miR-124-3p, miR-125-5p, miR-148a-3p and miR-93 (↑) in OP F vs. CTR | SNORD96a and RNU6 | miR-21-5p: 0.63, miR-23a-3p: 0.63, miR-24-3p: 0.63, miR-100-5p: 0.69, miR-122a-5p: 0.77, miR-124a-3p: 0.69, miR-125b-5p: 0.76, miR-148a-3p and miR-93: 0.68 | / | [64] |
| OP F (45), wnOF CTR (15) | / | Serum | / | qPCR | miR-24-3p, miR-27a-3p, miR-100, miR-125b, miR-122a and miR-145-5p (↑) in OP F vs. CTR | U6 | / | / | [69] |
| OP F (6), wnOF CTR (6) | / | Serum | / | qPCR | miR-363-3p, miR-214, miR-103a, miR-148a (↑), and miR-2861, miR-34a, miR-503 (↓) in OP F vs. CTR | / | / | / | [70] |
| PM: OP F (30), wnOF CTR (36) | DXA | Serum | / | qPCR | miR-483 (↑) in OP F vs. CTR | U6 | / | / | [71] |
↑: up-regulated, ↓: down-regulated, F: with fracture.